ArriVent BioPharma Inc. C...

NASDAQ: AVBP · Real-Time Price · USD
19.56
0.94 (5.05%)
At close: Aug 15, 2025, 3:46 PM

ArriVent BioPharma Common Stock Balance Sheet Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
74.29M 150.39M 163.37M 37.28M
Short-Term Investments
144.57M n/a n/a n/a
Long-Term Investments
47.68M n/a n/a 2K
Other Long-Term Assets
126K 2.84M 72K 87K
Receivables
500K 761K 500K 250K
Inventory
n/a n/a n/a n/a
Other Current Assets
n/a 8.69M n/a n/a
Total Current Assets
226.98M 159.97M 182.62M 42.95M
Property-Plant & Equipment
154K 291K 139K n/a
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
47.96M 3.13M 211K 89K
Total Assets
274.94M 163.1M 182.83M 43.04M
Account Payables
3.78M 4.53M 3.09M 293K
Deferred Revenue
n/a n/a n/a n/a
Short-Term Debt
162K n/a n/a n/a
Other Current Liabilities
-162K 3.6M 2.46M n/a
Total Current Liabilities
17.27M 11.62M 8.36M 1.82M
Long-Term Debt
n/a n/a n/a n/a
Other Long-Term Liabilities
n/a n/a n/a n/a
Total Long-Term Liabilities
14K 177K 11K n/a
Total Liabilities
17.29M 11.8M 8.37M 1.82M
Total Debt
176K 317K 139K n/a
Common Stock
3K n/a 4K 4K
Retained Earnings
-238.33M -157.84M -88.51M -51.61M
Comprehensive Income
-211K n/a -4K -4K
Shareholders Equity
257.65M 151.3M 174.46M 41.22M
Total Investments
192.25M n/a n/a 2K